Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab pharmacokinetics study in young pediatric IBD patients
NL-OMON23711Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis, sponsored by Erasmus MC. Primary endpoints: Clinical efficacy of infliximab treatment, Anthropometric data relationship and 3 more. Planned start Oct 2015; status: not yet recruiting.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON23711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23711.